Real-world data: providing better care today and reinventing the medicine of tomorrow

Real-world data: a lever for more effective medicine

Real-world data is the information contained in medical records and examination reports, patient feedback collected with the help of questionnaires or connected applications, or even population and administrative data. 

Coming from the "real world", this data reflect the daily lives of patients and hospital departments, and complement clinical trials. Unlike controlled trial data, they integrate the diversity of courses of care and the impact of treatments in real world conditions. By providing concrete evidence, they offer a better understanding of local and international disparities in the clinical management of the same recently marketed medicinal product or a specific subgroup of patients. 
Real-world data studies make it possible for us to evaluate the effectiveness and tolerability of treatments, identify unmet medical needs, optimize and personalize care, accelerate access to therapeutic innovations, and reduce the development costs of new medicinal products.

Real-world data also make it possible to create ethical alternatives to traditional trials, by reducing the use of placebo groups thanks to reliable synthetic models called "synthetic control arms". $

Institut Curie Health Data Warehouse: a valuable and secure resource

Thanks to its Health Data Warehouse , a first for a French Comprehensive Care Centre (CLCC) in France, Institut Curie has an exceptional heritage of real-world data, the result of the progressive digitization of 25 years of care for cancer patients. These precious data are pseudonymized and only accessible in highly secure workspaces, in accordance with CNIL regulations. This framework makes it possible to guarantee an ethical and responsible use of data while offering a fertile ground for collaborative research.

A dynamic active partnership for transforming patient care

At Institut Curie, real-world data is at the heart of an ambitious strategy aimed at advancing medical research. This vision has led to more than thirty collaborations with leading companies over the past five years.

Among them, a flagship partnership with IQVIA, world leader in clinical research and specialists in strategic consulting and analysis of health data, has given rise to numerous real-world studies on key indications: breast, lung and ovarian cancers. Initiated in 2019, this partnership positions Institut Curie as one of IQVIA's privileged partners in France within their "Oncology Evidence Network". This network, made up of European hospital centers of excellence in oncology, is dedicated to collaboration with the pharmaceutical industry to carry out projects based on real-world data. Institut Curie is also expanding on direct collaborations with leading players, such as Roche and BMS, in order to carry out national-scale studies coordinated by Institut Curie, thus strengthening its leading role in oncology innovation.

These partnerships provide crucial data for the approval of new treatments, reveal personalized therapeutic approaches, and optimize clinical practices. Being at the crossroads of clinical expertise and technological innovation, they directly contribute to improving the quality of life of patients.

Expert teams dedicated to data enhancement

The Data Department of Institut Curie, in collaboration with all institutional expertise, offers close and integrated support for companies and internal medical and scientific teams. This support aims to enhance real-world data at every stage, from its collection to its exploitation, by developing innovative projects around this data.

From the identification of patient cohorts to the mapping of available data, including feasibility studies and the provision of data in accordance with current regulations, each step is handled by expert teams, thus ensuring complete and rigorous management of the value chain.

Institut Curie's biometrics teams also play a central role in these studies by developing tailor-made statistical analysis plans and performing complex analyses that translate data into actionable knowledge. 
 

* Institut Curie is the first Cancer Control Center, and one of the first healthcare institutions in France, to have an authorization for its Health Data Warehouse (HDW) meeting the requirements of the CNIL standard in terms of safety in particular. The HDW authorized by the CNIL in 2024 will take effect in 2025.